Risperidone and atomoxetine in the treatment of severe and challenging behaviours in children with pervasive developmental disorders

Trial Profile

Risperidone and atomoxetine in the treatment of severe and challenging behaviours in children with pervasive developmental disorders

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Atomoxetine (Primary) ; Risperidone (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2015 New trial record
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top